Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.
Recombinant human interferon alfa-A (rIFN alpha A) had a dose-related suppressive effect on human T lymphotropic virus type III (HTLV-III) replication in vitro in normal peripheral-blood mononuclear cells (PBMC). Both single-dose and multiple-dose regimens were inhibitory. Such inhibitory concentrations (4-1024 units/ml) were not toxic to PBMC in culture, and were within the ranges achievable in blood after injection. These studies suggest that clinical trials of rIFN alpha A in early HTLV-III infection are warranted.
Ho
D D
DD
Hartshorn
K L
KL
Rota
T R
TR
Andrews
C A
CA
Kaplan
J C
JC
Schooley
R T
RT
Hirsch
M S
MS
D017977:Deltaretrovirus / Q000187:drug effects* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D007370:Interferon Type I / Q000494:pharmacology*; D007962:Leukocytes / Q000382:microbiology; D013997:Time Factors; D014779:Virus Replication / Q000187:drug effects*
D007370:Interferon Type I